MARKET

TLSI

TLSI

TriSalus Life Sciences Inc.
NASDAQ
7.06
+0.36
+5.37%
After Hours: 7.20 +0.14 +1.98% 18:57 12/05 EST
OPEN
6.79
PREV CLOSE
6.70
HIGH
7.27
LOW
6.61
VOLUME
129.13K
TURNOVER
--
52 WEEK HIGH
7.32
52 WEEK LOW
3.420
MARKET CAP
352.75M
P/E (TTM)
-3.5020
1D
5D
1M
3M
1Y
5Y
1D
TriSalus Life Sciences To Host Virtual KOL Event On Thyroid Disease And PED-TAE TriNav Infusion Approach On December 15, 2025 At 2:00pm ET
Benzinga · 2d ago
TriSalus Life Sciences Hosts Virtual KOL Event on TriNav Infusion System for Symptomatic Thyroid Disease
Reuters · 2d ago
Weekly Report: what happened at TLSI last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at TLSI last week (1117-1121)?
Weekly Report · 11/24 09:38
TriSalus Life Sciences: Strong Growth Prospects and Strategic Developments Reinforce Buy Rating
TipRanks · 11/21 12:15
TriSalus Life Sciences: Strong Revenue Growth and Strategic Initiatives Drive Buy Rating
TipRanks · 11/18 16:15
TRISALUS LIFE SCIENCES LAUNCHES TRINAV® XP INFUSION SYSTEM TO EXPAND OPTIONS FOR PRESSURE-ENABLED DRUG DELIVERY™
Reuters · 11/18 13:00
Weekly Report: what happened at TLSI last week (1110-1114)?
Weekly Report · 11/17 09:38
More
About TLSI
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.

Webull offers TriSalus Life Sciences Inc stock information, including NASDAQ: TLSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSI stock methods without spending real money on the virtual paper trading platform.